Bristol-Myers Squibb Co.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +4.9% (SPY −2.6%, XLV +9.9%). 3 months: −6.3% (SPY −2.2%, XLV +13.5%). 1 year: +34.1% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: BMY, SPY and XLV · as of 3 Nov 2026

2. 02

   P/E 70.0% below its peers' median

   Trailing P/E of 13.7 against a median of 45.7 across 5 peers named in its company record (range 39.5 to 115.7).

   Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026

3. 03

   Below its 50-day average, above its 200-day

   The 3 Nov 2026 close of $61.71 was 1.4% below its 50-day average ($62.61) and 2.8% above its 200-day average ($60.01). It has closed above the 200-day for 11 sessions, since 20 Oct 2026. The 50-day average crossed above the 200-day on 29 Dec 2025, 213 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

4. 04

   70% of the way up its 52-week range

   Closed at $61.71 on 3 Nov 2026: 10.1% below the 52-week high of $68.64 (19 Aug 2026) and 36.3% above the low of $45.27 (20 Nov 2025).

   Daily price bars, split-adjusted · as of 3 Nov 2026

5. 05

   Short interest at 2.4% of shares outstanding

   49.9M shares were sold short at the 15 Oct 2026 settlement, 2.4% of the 2.04B shares outstanding; covering them would take 3.6 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 3 Nov 2026 close